Last reviewed · How we verify

NCT05047003: RESTLESS

Oculogica Portable EyeBOX Study

Completed Last updated 7 September 2023
What this trial tests

trial testing EyeBOX Model EBX-4 (Portable version) in Concussion, Brain in 100 participants. Completed in 1 October 2022.

Timeline
19 December 2020
Primary endpoint
1 September 2022
1 October 2022

Quick facts

Lead sponsorOculogica, Inc.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment100
Start date19 December 2020
Primary completion1 September 2022
Estimated completion1 October 2022
Sites4 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Oculogica, Inc.

Who can join

Adults 5 to 67, any sex, with Concussion, Brain or Mild Traumatic Brain Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to assess the accuracy of a portable version of the EyeBOX device, an eye-tracking based diagnostic, in comparison to a clinical reference standard of concussion. The utility of the portable assessment to aid in the monitoring of symptoms over time after an initial diagnosis of concussion will also be evaluated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Concussion, Brain

Currently open trials in the same condition.

Other Oculogica, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05047003.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing